The primary focus of Project II is the analysis of the three-dimensional structure of the gonadotropins. This project collaborates with Project I and III, which supply some of the reagents and techniques to carry out this program. Solutions of the structures of the active and inactive forms of gonadotropins and their receptor interfaces will enable design of hormone agonists and antagonists which will be useful in the control of fertility. It is not possible to design such reagents without solved structures to supply the precise geometry information about the surfaces of the protein. The specific goals of this project are: (1) to determine the structures of the glycosylated biologically active form of hCG and of neuraminidase- treated hCG and to compare the resulting models to our solved structure of HF-treated hCG, an antagonist of hCG; (2) to determine the structure of the hormone receptor interface of hCG and the LH/CG receptor; (3) to determine the structure of FSH; (4) to determine the structure of the subunits of hCG; (5) to design mutants of hCG from its solved structure to produce an hCG antagonist by decreasing the flexibility of hCG; and (6) to continue to develop important novel technology for NMR solutions of three dimensional structures. The project encompasses biophysical methodology (Crystallography & NMR) to achieve these goals.

Project Start
1998-01-01
Project End
1999-12-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
17
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Birken, S; Krichevsky, A; O'Connor, J et al. (1999) Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient: generation of antibodies that differentiate between pregnancy hCG and choriocarcinoma hCG. Endocrine 10:137-44
Kovalevskaya, G; Birken, S; Kakuma, T et al. (1999) Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG. J Endocrinol 161:99-106
Lin, W; Ransom, M X; Myers, R V et al. (1999) Addition of an N-terminal dimerization domain promotes assembly of hCG analogs: implications for subunit combination and structure-function analysis. Mol Cell Endocrinol 152:91-8
Kovalevskaya, G; Birken, S; Kakuma, T et al. (1999) Evaluation of nicked human chorionic gonadotropin content in clinical specimens by a specific immunometric assay. Clin Chem 45:68-77
Ulaner, G A; Chuang, J; Lin, W et al. (1999) Desensitization and resensitization of lutropin receptors expressed in transfected Y-1 adrenal cells. J Endocrinol 163:289-97
O'Connor, J F; Kovalevskaya, G; Birken, S et al. (1998) The expression of the urinary forms of human luteinizing hormone beta fragment in various populations as assessed by a specific immunoradiometric assay. Hum Reprod 13:826-35
Lunardi-Iskandar, Y; Bryant, J L; Blattner, W A et al. (1998) Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease. Nat Med 4:428-34
Elliott, M M; Kardana, A; Lustbader, J W et al. (1997) Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 7:15-32
Campbell, R K; Bergert, E R; Wang, Y et al. (1997) Chimeric proteins can exceed the sum of their parts: implications for evolution and protein design. Nat Biotechnol 15:439-43
Cosowsky, L; Lin, W; Han, Y et al. (1997) Influence of subunit interactions on lutropin specificity. Implications for studies of glycoprotein hormone function. J Biol Chem 272:3309-14

Showing the most recent 10 out of 70 publications